Sarah Hedges

OmniSeq

OmniSeq, an innovation of Roswell Park Cancer Institute, is a molecular diagnostic laboratory based in Buffalo, New York. OmniSeq endeavors to find the right drug or the right trial for every patient by improving access to better cancer treatment options through molecular profiling. In addition to other NY State CLEP approved assays, OmniSeq offers OmniSeq Comprehensive and Immune Report Card. These two assays are available clinically in the United States and interrogate all known genomic and immune markers tied to approved therapeutics and clinical trials. OmniSeq is also making significant investments to create better diagnostics for immuno-oncology therapy selection. OmniSeq is proud to partner with pharmaceutical companies to provide research support for immuno-oncology development projects. For more information, call 1-800-781-1259 or visit www.omniseq.com.